Mukherjee Biswajit, Das Surajit, Chakraborty Samrat, Satapathy Bhabani Sankar, Das Pranab Jyoti, Mondal Laboni, Hossain Chowdhury Mobaswar, Dey Niladri Shekhar, Chaudhury Anumita
Research & Development, Procter & Gamble, 70 Biopolis Street, Singapore138547, Republic of Singapore.
Curr Drug Metab. 2014;15(6):565-80. doi: 10.2174/1389200215666140605150703.
Nanomaterials have made a significant impact on cancer therapeutics and an emergence of polymeric nanoparticle provides a unique platform for delivery of drug molecules of diverse nature. Nanoparticles can be targeted at the tumor cells due to enhanced permeability and retention effect. Moreover, nanoparticles can be grafted by various ligands on their surface to target the specific receptors overexpressed by cancer cells or angiogenic endothelial cells. These approaches ultimately result in longer circulation half-lives, improved drug pharmacokinetics, reduced side effects of therapeutically active substances and overcoming cancer chemo-resistance thereby enhancing the therapeutic efficacy of the treatment. This review article summarizes the recent efforts in cancer nanochemotherapeutics using polymeric nanoparticles with a special reference to their pharmacokinetic and biodistribution profiles, their role in reversing multidrug resistance in cancer and strategies of tumor targeting with them, along with the challenges in the field.
纳米材料对癌症治疗产生了重大影响,聚合物纳米颗粒的出现为多种性质的药物分子递送提供了一个独特的平台。由于增强的渗透和滞留效应,纳米颗粒可以靶向肿瘤细胞。此外,纳米颗粒可以在其表面接枝各种配体,以靶向癌细胞或血管生成内皮细胞过度表达的特定受体。这些方法最终导致更长的循环半衰期、改善药物药代动力学、降低治疗活性物质的副作用并克服癌症化疗耐药性,从而提高治疗的疗效。这篇综述文章总结了使用聚合物纳米颗粒进行癌症纳米化疗的最新进展,特别提及了它们的药代动力学和生物分布概况、它们在逆转癌症多药耐药性中的作用以及用它们进行肿瘤靶向的策略,以及该领域面临的挑战。